SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Lymphocytes and biomedical concept, 3d rendering. 3D illustration.
Cell therapy
5 CAR T Cell Therapies With Autoimmune Readouts in 2025
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune disorders, with several early- to mid-stage readouts expected this year.
March 17, 2025
 · 
9 min read
 · 
Tristan Manalac
illustration of people racing along arrows
Opinion
Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren
Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide catch up?
March 17, 2025
 · 
3 min read
 · 
Jia Jie Chen
3D illustration abstract background. Image of puzzle pieces in chrome gray metal.
GLP-1
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health outcomes—evidenced by successful studies in therapeutic areas like cardiovascular and sleep apnea—may prove a greater market advantage.
March 17, 2025
 · 
6 min read
 · 
Kate Goodwin
Vector illustration of a bottle of wine and a glass of wine on a yellow background in retro style.
GLP-1
Altimmune To Test Investigational GLP-1–Based Obesity Drug for Alcohol Use Disorder
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related conditions.
March 14, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Dashed line from pills isolated on white
Pipeline
Pfizer’s Pipeline Pruning Ends Early-Stage STING Trial
Pfizer was studying PF-07820435, an orally available agonist of the STING protein, for solid tumors.
March 14, 2025
 · 
2 min read
 · 
Tristan Manalac
cutting off a row of people into pieces
Layoffs
Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review
Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate luveltamab tazevibulin, which it was studying for ovarian cancer. The biotech will seek licensing opportunities for the asset.
March 14, 2025
 · 
3 min read
 · 
Tristan Manalac
Drug capsules with skull and crossbone on dark stone background.
Business
Pliant Pops Poison Pill as Concentra Threat Looms
Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect shareholders against Tang Capital’s growing stake in the company.
March 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative pattern made with a syringe on pastel pink background. Vaccine for Coronavirus infection. Pandemic concept.
Government
FDA Makes Flu Vaccine Recommendations Without Convening Advisors
The recommendations were made in a closed session with representatives from CBER, the CDC and Department of Defense.
March 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Vaccination against dangerous diseases. stock photo
Vaccines
Trump Administration Pulls CDC Nominee Dave Weldon at Last Minute
As Marty Makary and Jay Bhattacharya sail through the Senate health committee vote, Weldon’s confirmation hearing is canceled. Guggenheim Partners heralded the last-minute move to revoke Dave Weldon’s nomination as “a positive sign for reigning in vaccine criticism.”
March 13, 2025
 · 
1 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS